Ignite Creation Date:
2025-12-25 @ 3:54 AM
Ignite Modification Date:
2025-12-26 @ 2:44 AM
Study NCT ID:
NCT00039702
Status:
COMPLETED
Last Update Posted:
2008-03-04
First Post:
2002-06-06
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Brain Imaging in Alzheimer's Disease
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D000544', 'term': 'Alzheimer Disease'}], 'ancestors': [{'id': 'D003704', 'term': 'Dementia'}, {'id': 'D001927', 'term': 'Brain Diseases'}, {'id': 'D002493', 'term': 'Central Nervous System Diseases'}, {'id': 'D009422', 'term': 'Nervous System Diseases'}, {'id': 'D024801', 'term': 'Tauopathies'}, {'id': 'D019636', 'term': 'Neurodegenerative Diseases'}, {'id': 'D019965', 'term': 'Neurocognitive Disorders'}, {'id': 'D001523', 'term': 'Mental Disorders'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C426745', 'term': '5-iodo-3-(2-azetidinylmethoxy)pyridine'}]}}, 'protocolSection': {'designModule': {'studyType': 'OBSERVATIONAL', 'enrollmentInfo': {'count': 40}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2002-06'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2004-09', 'completionDateStruct': {'date': '2004-09'}, 'lastUpdateSubmitDate': '2008-03-03', 'studyFirstSubmitDate': '2002-06-06', 'studyFirstSubmitQcDate': '2002-06-06', 'lastUpdatePostDateStruct': {'date': '2008-03-04', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2002-06-07', 'type': 'ESTIMATED'}}, 'conditionsModule': {'keywords': ['Nicotinic Acetylcholine Receptors', "Alzheimer's Disease", 'SPECT', 'AD', 'Healthy Volunteer', 'HV', 'Normal Control'], 'conditions': ['Alzheimer Disease']}, 'referencesModule': {'references': [{'pmid': '7901908', 'type': 'BACKGROUND', 'citation': 'Coyle JT, Puttfarcken P. Oxidative stress, glutamate, and neurodegenerative disorders. Science. 1993 Oct 29;262(5134):689-95. doi: 10.1126/science.7901908.'}, {'pmid': '8346443', 'type': 'BACKGROUND', 'citation': "Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993 Aug 13;261(5123):921-3. doi: 10.1126/science.8346443."}, {'pmid': '8350998', 'type': 'BACKGROUND', 'citation': "Saunders AM, Strittmatter WJ, Schmechel D, George-Hyslop PH, Pericak-Vance MA, Joo SH, Rosi BL, Gusella JF, Crapper-MacLachlan DR, Alberts MJ, et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology. 1993 Aug;43(8):1467-72. doi: 10.1212/wnl.43.8.1467."}]}, 'descriptionModule': {'briefSummary': "The purpose of this study is to use brain imaging technology to examine the role of certain brain chemicals in individuals with Alzheimer's disease (AD) and in healthy volunteers.\n\nCognitive dysfunction in people with AD is thought to arise from decreased chemical activity in specific parts of the brain. Decreases in alpha4beta2 nicotinic acetycholine receptors (nAChRs) have been found in the brains of people who died with AD; however, the status of this receptor system in living brains remains unclear. This study will use single photon emission computed tomography (SPECT) to study this receptor system in people with AD who have mild to moderate dementia and in healthy volunteers. In addition, this study will examine the relationship between cognitive dysfunction and nAChR deficits in the brains of individuals with AD.\n\nParticipants with AD will have four clinic visits; healthy volunteers will have three visits. At Visit 1, participants will undergo a medical history, physical examination, and laboratory tests. Healthy volunteers will have a Mini-Mental State Examination (MMSE) cognitive function test. Participants with AD will have a MMSE and measurement of the severity of their dementia.\n\nDuring Visit 2, participants will undergo a magnetic resonance imaging (MRI) scan of the brain.\n\nAt Visit 3, participants will undergo SPECT imaging.\n\nOnly participants with AD will participate in Visit 4. During this visit, cognitive testing will be performed.", 'detailedDescription': 'Cognitive dysfunction in Alzheimer\'s disease (AD) patients are thought to arise in part from underlying losses of cholinergic input to cerebral cortex and hippocampus. Consistent marked decreases of alpha4beta2 nicotinic acetylcholine receptors (nAChRs) are found in postmortem AD brains. However, knowledge of the in vivo status of this receptor system is limited due to the lack of suitable tracers for PET/SPECT imaging. We plan to use a new SPECT tracer, \\[123I\\]5-I-A-85380, which appears suitable for imaging the alpha4beta2 subtype of nAChRs, in order to delineate abnormalities of this receptor system in a "subgroup" of 20 mild to moderately demented AD patients against 20 age matched healthy controls, the "subgroup" being characterized by carrying the AD susceptibility Apolipoprotein E epsilon4 allele. In addition, we plan to examine the relationship between cognitive dysfunction and alpha4beta2 nAChr deficits in the cerebral cortex and hippocampus of these AD patients. This study represents our initial effort toward our long-term goal of understanding the role this important receptor system plays in the pathophysiological mechanisms and drug manipulation of AD.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['CHILD', 'ADULT', 'OLDER_ADULT'], 'healthyVolunteers': True, 'eligibilityCriteria': "INCLUSION CRITERIA - ALZHEIMER'S DISEASE PATIENTS:\n\nAll AD patients will meet NINCDS-ADRDA criteria for probable AD with age of onset between 50 and 65 years of age.\n\nThe AD patients will be mild to moderately demented as assessed by the Mattis Dementia Rating Scale and Mini-Mental State Examination.\n\nIn particular, the AD patients will be nonsmokers because of known effects of smoking on nAChRs.\n\nPatients will be characterized by their APOE genotype as nAChR changes might be different with differing doses of this allele.\n\nWe will not exclude AD patients from participating while they are on AChe inhibitors.\n\nEXCLUSION CRITERIA - ALZHEIMER'S DISEASE PATIENTS:\n\nWe will exclude patients who are on galanthamine (Reminyl).\n\nWe will exclude patients on antidepressants and/or psychotropic drugs.\n\nINCLUSION CRITERIA - CONTROLS:\n\nNonsmoking healthy individuals who satisfy the inclusion and exclusion criteria."}, 'identificationModule': {'nctId': 'NCT00039702', 'briefTitle': "Brain Imaging in Alzheimer's Disease", 'organization': {'class': 'NIH', 'fullName': 'National Institutes of Health Clinical Center (CC)'}, 'officialTitle': "SPECT Imaging of Alpha4beta2 Nicotinic Acetylcholine Receptors Using [123I]5-I-A-85380 in Alzheimer's Disease", 'orgStudyIdInfo': {'id': '020058'}, 'secondaryIdInfos': [{'id': '02-M-0058'}]}, 'armsInterventionsModule': {'interventions': [{'name': '[123] 5-I-A-85380', 'type': 'DRUG'}]}, 'contactsLocationsModule': {'locations': [{'zip': '20892', 'city': 'Bethesda', 'state': 'Maryland', 'country': 'United States', 'facility': 'National Institute of Mental Health (NIMH)', 'geoPoint': {'lat': 38.98067, 'lon': -77.10026}}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'National Institute of Mental Health (NIMH)', 'class': 'NIH'}}}}